decrease font size
increase font size
change type face
bookmark this page
email this page
print this page
ThePigSite Latest News
Wednesday, May 02, 2007
Print This Page Circovirus Vaccine Receives Four-Month Duration of Immunity Approval
US - Boehringer Ingelheim Vetmedica, Inc., (BIVI) has announced that the U.S. Animal and Plant Health Inspection Service has approved a duration of immunity (DOI) claim for Ingelvac® CircoFLEX™ of at least four months for porcine circovirus type 2 (PCV2), the primary pathogen for porcine circovirus associated disease (PCVAD).
According to Klaas Okkinga, marketing manager for Boehringer Ingelheim, the approved DOI label extension substantiates extensive research findings that Ingelvac CircoFLEX provides long-lasting protection from PCV2.
"A vaccine that provides at least four months of PCV2 immunity is a significant benefit to producers in protecting pigs, both early and late, from damage caused by this disease," says Okkinga.
"Currently, Ingelvac CircoFLEX is the only PCV2 vaccine available with proven DOI of this length when administered as a single-dose to pigs 3 weeks of age or older," Okkinga adds.
"Even when administered early, it still protects through the critical period in grow-finish, resulting in reduced pig mortality and improved performance."
| ThePigSite News Desk | Read more Boehringer Ingelheim News here |
Latest Pig Industry News
CME: US Dollar the Currency of Choice
Pig Feed Production Reported to Be Down 15%
Record US Hog Slaughter Expected for Q4- China Holds Market Potential for US Pork
- USGC Helps Korean Industry Increase Productivity
- Voluntary Trichinae Certification Program Established
- IPPA: Salutations to Iowa's Pork Producers
Europeans Show Scepticism about Animal Cloning- Maple Leaf Explains Listeria Situation at its Plant
- New K-State Swine Building to Be Unveiled
